BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 30, 2012
 |  BioCentury  |  Product Development

A more rational antibody platform

How MorphoSys built Ylanthia antibody platform to replace HuCAL

With technology gained from its 2010 acquisition of Sloning BioTechnology GmbH, MorphoSys AG started from scratch to create Ylanthia, a new antibody library that will launch this year to replace the company's aging HuCAL platform.

MorphoSys was built on the success of HuCAL, an antibody phage display platform that launched in 1997. The platform has produced 77 programs in active development, 19 of which are in clinical testing.

CEO Simon Moroney told BioCentury that while this makes HuCAL the most successful antibody platform in the industry, technological advances have enabled the construction of a better library that will reduce the time needed to optimize lead candidates and increase the likelihood of success against difficult targets.

HuCAL -- short for human combinatorial antibody library -- is a collection of antibodies made by randomly pairing a set of seven variable heavy chains (VHs) and seven variable light chains (VLs). These 14 chains were predicted to be capable of producing over 95% of the natural diversity of human antibodies.

The library's diversity was generated in vitro using complementary determining region (CDR) cassettes synthesized by trinucleotide mutagenesis (TRIM). CDRs define an antibody's antigen-binding site. Swapping diversified CDR cassettes into the 49 possible VH-VL pairs led to the production...

Read the full 1003 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >